Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc reported that President Maya Martinez-Davis acquired notional American Depositary Shares through a company savings plan. The transaction involved 9.4103 ADS at a price of $50.7400 per ADS on the New York Stock Exchange on 2026-06-22, within her GSK Executive Supplemental Savings Plan account.
GSK plc reported that President Maya Martinez-Davis acquired notional American Depositary Shares through a company savings plan. The transaction involved 9.4103 ADS at a price of $50.7400 per ADS on the New York Stock Exchange on 2026-06-22, within her GSK Executive Supplemental Savings Plan account.
GSK plc has launched a cash tender offer to acquire all outstanding Class A and Class B shares of Nuvalent, Inc. for $124.00 per share. The offer is being made through Harmony Row Acquisition Co., a wholly owned subsidiary of GlaxoSmithKline LLC, under an Agreement and Plan of Merger dated June 9, 2026.
After the tender offer is completed and conditions are met, Harmony Row Acquisition Co. will merge into Nuvalent under Section 251(h) of the Delaware General Corporation Law, making Nuvalent a wholly owned subsidiary of GSK LLC. Nuvalent’s board has recommended that stockholders accept the offer. The offer and withdrawal rights are scheduled to expire at one minute after 11:59 p.m. Eastern Time on July 14, 2026, unless extended or terminated.
GSK plc has launched a cash tender offer to acquire all outstanding Class A and Class B shares of Nuvalent, Inc. for $124.00 per share. The offer is being made through Harmony Row Acquisition Co., a wholly owned subsidiary of GlaxoSmithKline LLC, under an Agreement and Plan of Merger dated June 9, 2026.
After the tender offer is completed and conditions are met, Harmony Row Acquisition Co. will merge into Nuvalent under Section 251(h) of the Delaware General Corporation Law, making Nuvalent a wholly owned subsidiary of GSK LLC. Nuvalent’s board has recommended that stockholders accept the offer. The offer and withdrawal rights are scheduled to expire at one minute after 11:59 p.m. Eastern Time on July 14, 2026, unless extended or terminated.
GSK plc reported a series of open‑market share purchases by its board leaders in June 2026. Non‑Executive Chair Sir Jonathan Symonds bought 1,550 ordinary shares at £19.3524 each on the London Stock Exchange on 2026-06-19. On 2026-06-22, several Independent Non‑Executive Directors, including Elizabeth McKee Anderson, Charles Bancroft, Anne Beal, Hal Dietz, Jeannie Lee and Vishal Sikka, purchased American Depositary Shares on the New York Stock Exchange at a price of $50.6908 per ADS in individual amounts ranging from 667 to 1,855 ADS.
GSK plc reported a series of open‑market share purchases by its board leaders in June 2026. Non‑Executive Chair Sir Jonathan Symonds bought 1,550 ordinary shares at £19.3524 each on the London Stock Exchange on 2026-06-19. On 2026-06-22, several Independent Non‑Executive Directors, including Elizabeth McKee Anderson, Charles Bancroft, Anne Beal, Hal Dietz, Jeannie Lee and Vishal Sikka, purchased American Depositary Shares on the New York Stock Exchange at a price of $50.6908 per ADS in individual amounts ranging from 667 to 1,855 ADS.
GSK plc reports purchases of its own ordinary shares between 15 and 19 June 2026 under its existing share buyback programme, executed through Citigroup Global Markets Limited. Daily purchases ranged from 209,874 to 245,840 shares, at volume-weighted average prices between 1,934.67 and 1,971.11 GBp per share.
The purchased shares will be held as treasury shares. Since 11 May 2026, GSK has bought 8,448,125 ordinary shares. After these transactions, it holds 269,826,411 shares in treasury and has 4,046,440,349 ordinary shares in issue, which is also the total number of voting rights.
The company states that, following these purchases, 6.67 per cent of voting rights are attributable to ordinary shares held in treasury, which shareholders can use as the denominator for disclosure calculations under UK transparency rules.
GSK plc reports purchases of its own ordinary shares between 15 and 19 June 2026 under its existing share buyback programme, executed through Citigroup Global Markets Limited. Daily purchases ranged from 209,874 to 245,840 shares, at volume-weighted average prices between 1,934.67 and 1,971.11 GBp per share.
The purchased shares will be held as treasury shares. Since 11 May 2026, GSK has bought 8,448,125 ordinary shares. After these transactions, it holds 269,826,411 shares in treasury and has 4,046,440,349 ordinary shares in issue, which is also the total number of voting rights.
The company states that, following these purchases, 6.67 per cent of voting rights are attributable to ordinary shares held in treasury, which shareholders can use as the denominator for disclosure calculations under UK transparency rules.
GSK reports that the US FDA has approved Utebzi (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis, who have limited or no alternative oral options.
The approval is based on the phase III PIVOT-PO trial, where oral tebipenem pivoxil 600 mg achieved a 58.5% overall success rate versus 60.2% for intravenous imipenem-cilastatin 500 mg, meeting the preset non-inferiority margin. Safety was generally similar to comparator carbapenems, with mostly mild to moderate diarrhoea and headache.
cUTIs account for more than 3 million cases annually in the US and over $6 billion in healthcare costs, with treatment failure affecting up to 34% of patients. Tebipenem pivoxil is anticipated to be available to US patients by the end of 2026 and extends GSK’s anti-infectives portfolio under its collaboration with Spero Therapeutics.
GSK reports that the US FDA has approved Utebzi (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis, who have limited or no alternative oral options.
The approval is based on the phase III PIVOT-PO trial, where oral tebipenem pivoxil 600 mg achieved a 58.5% overall success rate versus 60.2% for intravenous imipenem-cilastatin 500 mg, meeting the preset non-inferiority margin. Safety was generally similar to comparator carbapenems, with mostly mild to moderate diarrhoea and headache.
cUTIs account for more than 3 million cases annually in the US and over $6 billion in healthcare costs, with treatment failure affecting up to 34% of patients. Tebipenem pivoxil is anticipated to be available to US patients by the end of 2026 and extends GSK’s anti-infectives portfolio under its collaboration with Spero Therapeutics.
GSK plc reports further share repurchases under its existing buyback programme. Between 8 and 12 June 2026, the company, via Citigroup Global Markets Limited, bought a series of ordinary shares of 31¼ pence each on UK exchanges at prices around the high-1,800 to low-2,000 GBp range.
The purchased shares will be held as Treasury shares. Since 11 May 2026, GSK has bought a total of 7,346,236 ordinary shares. After the latest purchases, GSK holds 268,724,522 ordinary shares in treasury and has 4,047,527,077 ordinary shares in issue excluding treasury.
The total number of voting rights is now 4,047,527,077, and GSK states that 6.64 per cent of voting rights are attributable to treasury shares, which investors can use when assessing disclosure thresholds under UK transparency rules.
GSK plc reports further share repurchases under its existing buyback programme. Between 8 and 12 June 2026, the company, via Citigroup Global Markets Limited, bought a series of ordinary shares of 31¼ pence each on UK exchanges at prices around the high-1,800 to low-2,000 GBp range.
The purchased shares will be held as Treasury shares. Since 11 May 2026, GSK has bought a total of 7,346,236 ordinary shares. After the latest purchases, GSK holds 268,724,522 ordinary shares in treasury and has 4,047,527,077 ordinary shares in issue excluding treasury.
The total number of voting rights is now 4,047,527,077, and GSK states that 6.64 per cent of voting rights are attributable to treasury shares, which investors can use when assessing disclosure thresholds under UK transparency rules.
GSK plc reports that its JAK inhibitor momelotinib has received Orphan Drug Designation from both the US FDA and the EMA for treating VEXAS syndrome, a rare and life-threatening haemato-inflammatory disorder with no approved therapies.
The decision draws on case studies suggesting JAK inhibitors, including momelotinib, may help reduce VEXAS-related symptoms, inflammation and blood complications. A planned phase II/III ATLAS trial will evaluate momelotinib’s efficacy and safety in VEXAS and is intended to support global regulatory submissions as part of a broader haematology development programme.
Momelotinib (Ojjaara/Omjjara) is already approved in the US, EU, UK and Japan for various myelofibrosis indications in adults with anaemia or disease-related symptoms, and has a differentiated mechanism targeting JAK1, JAK2 and ACVR1 signalling pathways.
GSK plc reports that its JAK inhibitor momelotinib has received Orphan Drug Designation from both the US FDA and the EMA for treating VEXAS syndrome, a rare and life-threatening haemato-inflammatory disorder with no approved therapies.
The decision draws on case studies suggesting JAK inhibitors, including momelotinib, may help reduce VEXAS-related symptoms, inflammation and blood complications. A planned phase II/III ATLAS trial will evaluate momelotinib’s efficacy and safety in VEXAS and is intended to support global regulatory submissions as part of a broader haematology development programme.
Momelotinib (Ojjaara/Omjjara) is already approved in the US, EU, UK and Japan for various myelofibrosis indications in adults with anaemia or disease-related symptoms, and has a differentiated mechanism targeting JAK1, JAK2 and ACVR1 signalling pathways.
GSK plc reports that several senior leaders and one person closely associated with a leader acquired small amounts of company stock through its Share Reward Plan. On 2026-06-09, each transaction involved GSK ordinary shares of 31 ¼ pence each, traded on the London Stock Exchange.
Executives including President Europe Lynn Baxter, Chief Financial Officer Julie Brown, and other senior leaders acquired either 14 or 12 ordinary shares each at a price of £18.8393 per share, split between partnership and matching shares. These are routine share plan acquisitions rather than open-market trades.
GSK plc reports that several senior leaders and one person closely associated with a leader acquired small amounts of company stock through its Share Reward Plan. On 2026-06-09, each transaction involved GSK ordinary shares of 31 ¼ pence each, traded on the London Stock Exchange.
Executives including President Europe Lynn Baxter, Chief Financial Officer Julie Brown, and other senior leaders acquired either 14 or 12 ordinary shares each at a price of £18.8393 per share, split between partnership and matching shares. These are routine share plan acquisitions rather than open-market trades.
GSK plc reported that Maya Martinez-Davis, President, acquired notional American Depositary Shares through her GSK Executive Supplemental Savings Plan account. The transaction involved 9.4289 ADS at a price of $50.6400 per ADS on 2026-06-08, executed on the New York Stock Exchange.
GSK plc reported that Maya Martinez-Davis, President, acquired notional American Depositary Shares through her GSK Executive Supplemental Savings Plan account. The transaction involved 9.4289 ADS at a price of $50.6400 per ADS on 2026-06-08, executed on the New York Stock Exchange.
GSK plc reported a change in the outside roles of one of its board members. Dr Hal Barron, a Non-Executive Director at GSK, was appointed an Independent Director and Chair of the Nominating and Corporate Governance Committee of Quantinuum Inc. on 4 June 2026.
The company notes this appointment in line with UK Listing Rule 6.4.9R(2). GSK remains a global biopharma company focused on uniting science, technology and talent to get ahead of disease.
GSK plc reported a change in the outside roles of one of its board members. Dr Hal Barron, a Non-Executive Director at GSK, was appointed an Independent Director and Chair of the Nominating and Corporate Governance Committee of Quantinuum Inc. on 4 June 2026.
The company notes this appointment in line with UK Listing Rule 6.4.9R(2). GSK remains a global biopharma company focused on uniting science, technology and talent to get ahead of disease.